After years 4 years of wild volatility, things seem to have calmed down at ATAI, and things are moving sideways – with an upward bias. Hmm.
We last added ATAI to the Watch List (2024 list) at $1.80, in a ‘double down.’ We added it to the Watch List, after it plunged 44% in one day (which is a big deal after dropping from $18 to $4.00) after their depression treatment, got less than favorable news from the FDA. Earlier bargain hunters at $4.00, got a lesson in bargain hunting!
It’s of course not unusual for a stock to drop 40% in one day. But dropping 40% AFTER dropping 80%, now that’s unusual. At a certain point one can think everyone who wanted to sell has already sold…
ATAI Life Sciences’ Drug Trial For Depression Fails To Deliver Expected Results, Stock Plunges 44%.
Adding ATAI (ATAI) to 2024 Watch List. Doubling Down at $1.80
LIVE QUOTE
Now you might ask yourself, how can a stock that runs from $1.50 to $4.00 in a couple months, be described as moving ‘sideways?’ Well you have to look a little longer term…
LONGER TERM CHART
AND WALL STREET SAYS
Wall Street analyst’s are still bullish on ATAI’s long term (and bold means we do mean long..) prospects, as we are. Of course that couldn’t prevent it from falling from $18 to $1.73 in 2023
RECENT NEWS
TD Cowen, Leerink Partners, Guggenheim Securities and Berenberg raise $50 million! atai Life Sciences Announces $50 Million Private Placement Financing (July 1st)
Atai and Recognify’s Schizophrenia Drug Fails to Meet Main Goal in Trial (July 25th)
About atai Life Sciences
atai is a clinical-stage biopharmaceutical company on a mission to develop highly effective mental health treatments to transform patient outcomes. atai’s pipeline of psychedelic-based therapies includes BPL-003 (mebufotenin benzoate) for treatment-resistant depression (TRD), which is being advanced through a planned strategic combination with Beckley Psytech Limited; VLS-01 (buccal film DMT) also for TRD; and EMP-01 (oral R-MDMA) for social anxiety disorder. All three programs are in Phase 2 clinical development. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD. These programs aim to address the complex nature of mental health providing commercially scalable interventional psychiatry therapies that can integrate seamlessly into healthcare systems. For the latest updates and to learn more about atai’s mission, visit www.atai.com or follow the Company on LinkedIn and on X.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “initiate,” “could,” “would,” “project,” “plan,” “potentially,” “preliminary,” “likely,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these words. All statements in this press release other than statements of historical fact are forward-looking statements, including, express or implied statements relating to, among other things: statements regarding Recognify Life Science’s inidascamine (formerly RL-007) studies, data, or related strategic plans and objectives of management for future operations, capital expenditures and capital allocation. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond our control and which could cause actual results, levels of activity, performance, or achievements to differ materially from those expressed or implied by these forward-looking statements.
Forward-looking statements are neither promises nor guarantees, but involve known and unknown risks and uncertainties that could cause actual results to differ materially from those projected, including, without limitation, the important factors described in the section titled “Risk Factors” in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”), as such factors may be updated from time to time in atai’s other filings with the SEC. atai disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release, other than to the extent required by applicable law.
Contact Information
Investor Contact:
IR@atai.com
atai Media Contact:
PR@atai.com
